Such a model will become an important component of the University of Virginia (UVa)/Padova T1D Simulator [14], an in silico platform accepted by the Food and Drug Administration (FDA) as a substitute for preclinical trials for certain insulin treatments, including closed-loop algorithms for artificial pancreas [15], recently used as an ideal test bench for the development and evaluation of glucose sensors [16] and novel insulin analogues [17,18]. Here, INS is linked to type 1 diabetes mellitus.